Ipilimumab
Stage IV Vulvar Cancer AJCC v7
National Cancer Institute (NCI)monoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 95/ 100
Competitive context
9 Active assets in the Stage IV Vulvar Cancer AJCC v7 cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide HRYZ Biotech Co. | Phase 2 | B |
6-[4-(1-Cyclohexyl-1H-tetrazol-5-yl)butoxy]-3,4-dihydrocarbostyril Emory University | Phase 2 | CCC |
Nivolumab National Cancer Institute (NCI) | Phase 2 | CCC |
Pembrolizumab Merck Sharp & Dohme LLC | Phase 2 | CCC |
Plasmid Encoded Il-12 M.D. Anderson Cancer Center | Phase 2 | CCC |
View all 19 →
Same molecule, other indications
Ipilimumab is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →